Corticotropin
The pituitary hormone sold as Acthar Gel: approved for infantile spasms, debated for much else
Corticotropin, or ACTH, is the pituitary hormone that drives the adrenal glands to make cortisol. In the US it is sold as long-acting gels from pig pituitaries, Acthar Gel and Purified Cortrophin Gel, for infantile spasms, multiple sclerosis relapses and older inflammatory indications.
Manufacturer's recommended dosing (FDA label): 150 U/m²/day as 75 U/m² twice daily, Twice daily, Intramuscular (vial only) Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
ACTH is released by the pituitary and stimulates cortisol from the adrenal glands. Injected as a solution it lasts only about 15 minutes in the blood, so the US products are 'repository' gels that release it slowly. Acthar Gel was first approved in 1952 and Purified Cortrophin Gel in 1954, with long lists of older indications approved before modern trial standards.
The Acthar Gel label lists two modern indications first: monotherapy for infantile spasms in children under 2, and exacerbations of multiple sclerosis in adults. For infantile spasms it is given into muscle at 150 units/m² a day, split into two injections, for two weeks and then tapered off over two more; for MS relapses the dose is 80 to 120 units a day for two to three weeks. A long list of older rheumatic, skin, allergic, eye, lung and kidney uses follows, usually at 40 to 80 units every 24 to 72 hours.
Its clearest modern evidence is in infantile spasms, a severe epilepsy of babies: in a small randomised trial, 13 of 15 infants on high-dose ACTH responded against 4 of 14 on prednisone, and H.P. Acthar Gel was approved for infantile spasms in 2010. Elsewhere the evidence is thinner, from a nephrotic syndrome trial stopped for lack of efficacy to eye-disease use resting on case reports. Later trials against high-dose prednisolone narrowed the gap: meta-analyses of five and of nine randomised trials found no significant difference in stopping spasms at two weeks, though in the larger one ACTH improved the electroclinical response and delayed relapse, and at US prices high-dose prednisolone was far more cost-effective, with ACTH costing about $1.4 million per extra case resolved. When a first treatment fails, a ketogenic diet did better as the second treatment than ACTH in one trial cohort. In a small Indian trial ACTH and prednisolone stopped spasms about equally (50% against 40%), and as a first treatment in Vienna the ketogenic diet matched high-dose ACTH at day 28 with far fewer adverse effects needing treatment (30% against 94%), though ACTH worked faster in infants who had not had vigabatrin.
In multiple sclerosis relapses it has never beaten steroids. A 1989 double-blind trial in 61 patients found no difference in recovery between intravenous methylprednisolone and intramuscular ACTH, and both groups improved markedly. In a 2023 trial in 37 people with acute optic neuritis, repository corticotropin and intravenous methylprednisolone produced the same thinning of the retinal nerve fibre layer at six months (-13.1 against -11.7 µm). A small 2022 placebo-controlled trial in 35 people whose relapse had not responded to high-dose steroids found more responders on corticotropin; its lead author reported fees from the manufacturer.
Acthar is not interchangeable with synthetic ACTH, producing about fivefold lower cortisol exposure in volunteers, and it is among the most expensive old drugs in the US. Its label warns of infections, Cushing's syndrome and adrenal insufficiency on withdrawal, raised blood pressure, gastrointestinal bleeding, mood changes and effects on growth and bone.
Its effects are a steroid's effects, and the label says so: they are related primarily to the cortisol it releases. It warns that it may raise the risk of infections, that live vaccines are contraindicated at immunosuppressive doses, may cause fetal harm, and that prolonged use in children can slow growth. It also says it can add to the potassium and electrolyte loss of diuretics, and that no formal drug interaction studies have been done.
Mechanism of Action
ACTH stimulates the adrenal glands to release cortisol; the label attributes the drug's effects primarily to that steroid release.
Adrenal cortisol release
Corticotropin acts on the adrenal cortex, which releases cortisol; most of its benefits and side effects follow from that (label).
Slow-release gel
ACTH lasts about 15 minutes in the blood after an intravenous dose, so the products are repository gels injected into muscle or under the skin (label).
Not synthetic ACTH
In volunteers it produced about fivefold lower cortisol exposure than a synthetic ACTH(1-24) depot.
Published Research
The studies behind corticotropin, read from their PubMed abstracts: infantile spasms, multiple sclerosis and optic neuritis against steroids, and pharmacology against synthetic ACTH.
High-dose ACTH vs prednisone for infantile spasms
In a randomised trial with a blinded assessor, 13 of 15 infants given ACTH for two weeks stopped spasms and cleared the hypsarrhythmic EEG (86.6%), against 4 of 14 on prednisone (28.6%).
MS relapse: ACTH against IV methylprednisolone
In a double-blind randomised trial in 61 patients, both groups improved markedly, with no difference in the rate of recovery or the final outcome.
Acute optic neuritis: against IV methylprednisolone
37 people were randomised; at six months retinal nerve fibre layer loss was -13.1 µm on repository corticotropin and -11.7 µm on methylprednisolone (P = 0.88), with similar visual recovery.
MS relapse not responding to steroids
In 35 patients randomised to repository corticotropin or placebo, more were disability-score responders on corticotropin at days 7, 21 and 42, with no serious adverse events; the lead author reported fees from the manufacturer.
ATLANTIS: childhood nephrotic syndrome
A randomised trial in frequently relapsing childhood nephrotic syndrome was stopped at an interim analysis after 31 participants for lack of efficacy: 93% relapsed within six months on ACTH and 94% in the control group, with similar times to first relapse.
Acthar vs synthetic ACTH depot
In 48 healthy adults, two doses of repository corticotropin produced about fivefold lower free cortisol exposure, and about fourfold lower estimated steroid exposure, than synthetic ACTH 1-24 depot; the authors conclude the products are not interchangeable.
Chronic pulmonary sarcoidosis
In an open study of 16 patients completing 24 weeks, prednisone doses fell and lung diffusion, PET uptake and quality-of-life scores improved, but forced vital capacity did not change; the lower dose worked as well and was better tolerated.
After a first treatment fails
In infants with infantile epileptic spasms syndrome not seizure-free after first-line ketogenic diet or ACTH in a randomised trial, sustained seizure freedom after switching came in 50% (12 of 24) given the ketogenic diet second, 19% (3 of 16) given ACTH second and 9% given anti-seizure medicines; cumulative response after two treatments was 64-68% in either order.
West syndrome in India: no clear difference from prednisolone
In a randomised single-blind study in 33 children with West syndrome in India, spasms stopped in 9 of 18 (50%) on ACTH and 6 of 15 (40%) on prednisolone, with similar relapse, side effects, later epilepsy and development; the authors call prednisolone a suitable alternative where resources are poor, given the small sample.
Ketogenic diet against high-dose ACTH
In a parallel-cohort randomised trial in 101 infants with West syndrome (32 randomised), electroclinical remission at day 28 was similar on the ketogenic diet and high-dose ACTH (47% against 48% combined), relapse was lower on the diet (16% against 43%, not significant) and adverse effects needing intervention were far more frequent on ACTH (94% against 30%); without prior vigabatrin, ACTH gave more early remission (80% against 47%).
Publication bias and cost in eye disease
A review of its use in eye inflammation finds evidence limited to case reports, small series and open-label studies prone to positive publication bias, with unclear advantages over far cheaper oral steroids, and estimates yearly costs of $480,000 to $850,000.
Neuroinflammation in infantile spasms
In children with infantile spasms imaged before and after Acthar Gel, focal increases in a neuroinflammation tracer seen in five were reduced or normalised after treatment, as spasms stopped or fell sharply.
Infantile spasms: oral steroids matched ACTH
A meta-analysis of five randomised trials (239 infants) found no significant difference between oral corticosteroids and ACTH in stopping spasms by day 13-14 (odds ratio 0.54, confidence interval 0.16-1.81), nor in hypsarrhythmia resolution, side effects, relapse or later epilepsy; the authors conclude high-dose prednisolone is not inferior.
Infantile spasms: nine trials and the price
Pooling nine randomised trials of ACTH against prednisolone for infantile epileptic spasms syndrome, spasm cessation at day 14 did not differ (risk ratio 1.05) nor did total adverse events, though ACTH improved the electroclinical response (1.46) and delayed relapse; in China a 14-day course cost about 5,629 yuan against 5.56 yuan for prednisolone.
Cost-effectiveness: high-dose prednisolone
Pooling 21 studies (968 patients), spasm resolution at 14 days did not differ significantly between ACTH and oral steroids (0.70 against 0.63), and in three randomised trials (185 patients) the odds ratio against high-dose prednisolone was 0.92; at US prices prednisolone was far more cost-effective, with ACTH at about $1.43 million per extra case resolved.
Dosing Data
Acthar Gel is injected into muscle or under the skin; the label sets doses by indication.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Acthar (repository corticotropin injection): Injection available as: 5 mL multi-dose vial containing 80 USP units/mL, for intramuscular or subcutaneous use. 40 USP Units/0.5 mL Acthar Gel single-dose pre-filled SelfJect injector for subcutaneous injection. Forms the label lists: multiple-dose vials.
Source: Acthar (repository corticotropin injection) label, section 3 (DailyMed version 32, effective October 13, 2026).
Mixing a vial: a worked example
Nothing to mix: the label gives Acthar (repository corticotropin injection) as multiple-dose vials, ready to use.
Source: Acthar (repository corticotropin injection) label, sections 2, 3 and 16 (DailyMed version 32, effective October 13, 2026).
Storage before and after mixing
Before mixing or first use: “Store Acthar Gel vial and Acthar Gel single-dose pre-filled SelfJect injector under refrigeration between 2°C to 8°C (36°F to 46°F) in the carton to protect from light.” “After removing the single-dose pre-filled SelfJect injector from the refrigerator, it can be stored at room temperature between 20°C to 25°C (68°F to 77°F) for up to 24 hours.” “Do not heat, freeze, or put the Acthar Gel single-dose pre-filled SelfJect injector into direct sunlight.”
After mixing or first use: the label sentences we read say nothing separate about this.
Source: Acthar (repository corticotropin injection) label, sections 16 and 2 (DailyMed version 32, effective October 13, 2026).
How it is taken
As the approved label gives it: Intramuscular (vial only) (Twice daily; Label: infantile spasms); Intramuscular or subcutaneous (Once daily; Label: MS exacerbations).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of about 15 minutes in plasma after intravenous ACTH (label); the gel's pharmacokinetics are not adequately characterised. After about five half-lives almost none is left.
How long the doses were given: Label: infantile spasms: 2 weeks, then taper over 2 weeks; Label: MS exacerbations: 2 to 3 weeks; may need taper; Label: other indications: Individualised; may need taper.
When effects appear: unknown; no source on this page gives a time to effect for Corticotropin. Results reported in the studies are under Published Research.
Source: half-life: Acthar Gel prescribing information, section 12.3 (DailyMed set 7b48ddec, version 32, effective October 13, 2026); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Steroid effects: the label attributes its adverse effects primarily to the cortisol it releases; Hormonal side effects during high-dose treatment of infants; Raised blood pressure, fluid retention and low potassium; Behavioural and mood disturbances. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Corticotropin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the trials above and the Acthar Gel prescribing information (DailyMed set 7b48ddec, version 32, effective October 13, 2026)”).
Interactions
- diuretics: may accentuate diuretic-associated electrolyte loss; no formal interaction studies were performed
Every peptide's record, with its source: the interaction matrix.
Source: Mallinckrodt. ACTHAR GEL (repository corticotropin injection) US prescribing information, section 7. DailyMed version 32, effective October 13, 2026, read October 27, 2026.
Checking what you bought
Unknown: no published independent test of Corticotropin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as Acthar Gel (Mallinckrodt), NDA 008372, first approved April 29, 1952, with the infantile spasms application H.P). Sport: Prohibited at all times (S2.2.2).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the trials above and the Acthar Gel prescribing information (DailyMed set 7b48ddec, version 32, effective October 13, 2026).
Contraindications & Cautions
Warnings from the label.
Legal Status
Corticotropin is approved in the US as two repository gels.
Frequently Asked Questions
?What is Acthar Gel used for?
Infantile spasms in children under 2 and acute relapses of multiple sclerosis in adults, plus older inflammatory indications.
?Is Acthar the same as synthetic ACTH?
No. In volunteers it produced about fivefold lower cortisol exposure than a synthetic ACTH depot; the two are not interchangeable.
?Why is Acthar so expensive?
A 2022 review estimated yearly costs of $480,000 to $850,000 and found much of the evidence limited to small, open-label studies.
?Does it work better than steroids for MS relapses?
Not in head-to-head trials: a 1989 trial found no difference from intravenous methylprednisolone, and a 2023 optic neuritis trial found the same nerve outcomes with either.
?What dose is used for infantile spasms?
The label gives 150 units/m² a day into muscle, split into two injections, for two weeks, then tapered off over two weeks.
?Does it interact with other drugs?
The label says no formal interaction studies have been done, but that it can add to the electrolyte loss caused by diuretics.
References
- [fda] US FDA, Drugs@FDA (openFDA): ACTHAR GEL, NDA 008372 (April 29, 1952); H.P. ACTHAR GEL, NDA 022432 (October 15, 2010); PURIFIED CORTROPHIN GEL, NDA 008975 (June 16, 1954). Read October 3, 2026.
- [fda-pi] FDA. Acthar Gel (repository corticotropin injection) US prescribing information (DailyMed set 7b48ddec-e815-45f4-9ca0-5c0daaf56f30, version 32, effective October 13, 2026). Read October 3, 2026 (version and date updated to the current SPL, October 27, 2026).
- [fda-pi] FDA. Purified Cortrophin Gel (repository corticotropin injection) US prescribing information (DailyMed set f27544ee-a0e2-4d84-b193-1c9efdf9e34c, version 15, effective October 5, 2026). Read October 3, 2026 (version and date updated to the current SPL, October 27, 2026).
- [pubmed] Baram TZ, et al. "High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study." Pediatrics, 1996;97(3):375-9. PMID: 8604274.
- [pubmed] Thompson AJ, et al. "Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS." Neurology, 1989;39(7):969-71. PMID: 2544829.
- [pubmed] Bennett JL, et al. "A Randomized Prospective Trial Comparing Repository Corticotropin Injection and Intravenous Methylprednisolone for Neuroprotection in Acute Optic Neuritis." J Neuroophthalmol, 2023;43(3):323-329. PMID: 37261907.
- [pubmed] Wynn D, et al. "Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids." CNS Neurosci Ther, 2022;28(3):364-371. PMID: 34984839.
- [pubmed] Wang CS, et al. "Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial." Clin J Am Soc Nephrol, 2018;13(12):1859-1865. PMID: 30442868.
- [pubmed] Poola N, et al. "Pharmacokinetics and Pharmacodynamics of Repository Corticotropin Injection Compared With Synthetic ACTH(1-24) Depot and Methylprednisolone in Healthy Subjects." Clin Pharmacol Drug Dev, 2022;11(4):502-515. PMID: 34528408.
- [pubmed] Baughman RP, et al. "Repository corticotropin for Chronic Pulmonary Sarcoidosis." Lung, 2017;195(3):313-322. PMID: 28353116.
- [pubmed] Lobo-Chan AM, et al. "Publication bias, Open-Labeled Trials and Sky Rocketing Costs- Past, Present and Future of Repository Corticotropin Injection?." Ocul Immunol Inflamm, 2022;30(6):1505-1507. PMID: 34242098.
- [pubmed] Chugani HT, et al. "Neuroinflammation in Children With Infantile Spasms: A Prospective Study Before and After Treatment With Acthar Gel (Repository Corticotropin Injection)." J Child Neurol, 2020;35(12):808-812. PMID: 32576069.
- [pubmed] Chang YH, et al. "Effectiveness of corticosteroids versus adrenocorticotropic hormone for infantile spasms: a systematic review and meta-analysis." Ann Clin Transl Neurol, 2019;6(11):2270-2281. PMID: 31657133.
- [pubmed] Gao R, et al. "Adrenocorticotropic Hormone versus Prednisolone for Infantile Epileptic Spasms Syndrome: A Systematic Review and Economic Evaluation." Neuropediatrics, 2025;56(2):102-110. PMID: 39900086.
- [pubmed] Sánchez Fernández I, et al. "Cost-effectiveness of adrenocorticotropic hormone versus oral steroids for infantile spasms." Epilepsia, 2021;62(2):347-357. PMID: 33417252.
- [pubmed] Dressler A, et al. "Role of the Ketogenic Diet Therapy and ACTH as Second Treatments in Drug-Resistant Infantile Epileptic Spasms Syndrome." Nutrients, 2025;17(13). PMID: 40647190.
- [pubmed] Gowda VK, et al. "Corticotrophin-ACTH in Comparison to Prednisolone in West Syndrome - A Randomized Study." Indian J Pediatr, 2019;86(2):165-170. PMID: 30232789.
- [pubmed] Dressler A, et al. "Efficacy and tolerability of the ketogenic diet versus high-dose adrenocorticotropic hormone for infantile spasms: A single-center parallel-cohort randomized controlled trial." Epilepsia, 2019;60(3):441-451. PMID: 30801699.
Sources & Citations
Studies were read from their PubMed records (October 5, 2026); the labels and Drugs@FDA are listed below with their read dates.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.